Results 281 to 290 of about 58,205 (308)

Outcome of Metastatic Biliary Tract Cancer Harbouring <i>IDH1</i> or <i>FGFR2</i> Alterations: A Retrospective Observational Real-World Study from a French Cohort. [PDF]

J Clin Med
Barbe-Richaud JB, Moinard-Butot F, Cotton M, Bigot C, Rivière P, Belletier C, Pencreach E, Karouby D, Chiappa P, Eberst L, Kurtz JE, Ben Abdelghani M.   +11 more
europepmc   +1 more source

Expanding Horizons in Cholangiocarcinoma: Emerging Targets Beyond FGFR2 and IDH1. [PDF]

Int J Mol Sci
Darman L, Kaurich Q, Hassan MS, von Holzen U, Awasthi N.   +4 more
europepmc   +1 more source

Role of Multiparametric Ultrasound in Predicting the IDH Mutation in Gliomas: Insights from Intraoperative B-Mode, SWE, and SMI Modalities. [PDF]

J Clin Med
Cai S, Xing H, Wang Y, Wang Y, Ma W, Jiang Y, Li J, Wang H.   +7 more
europepmc   +1 more source

Olutasidenib for mutated IDH1 acute myeloid leukemia: final five-year results from the phase 2 pivotal cohort. [PDF]

J Hematol Oncol
Cortes J, Curti A, Fenaux P, Jonas BA, Krauter J, Montesinos P, Récher C, Taussig DC, Wang ES, Watts J, Wei A, Yee KW, Tian H, Sheppard A, Marzac C, de Botton S.   +15 more
europepmc   +1 more source

Assessing glymphatic dysfunction using the diffusion tensor image analysis along the perivascular space (DTI-ALPS) index in gliomas and metastases. [PDF]

Pol J Radiol
Jayanna D, Kankara SR, K SR, Josephine A, Tellis VM, Kancharla M, Monteiro AA, Kumaran SP, Deepalam SR.   +8 more
europepmc   +1 more source

IDH1 Mutations Alter Citric Acid Cycle Metabolism and Increase Dependence on Oxidative Mitochondrial Metabolism

, 2014
Alexandra Grassian, Seth J. Parker, Ajit S. Divakaruni, C. R. Green, X. Zhang, Kelly L. Slocum, Minying Pu, Fallon Lin, Chad Vickers, Carol Joud-Caldwell, Florence H. T. Chung, Hong Yin, Erika D. Handly, Christopher Straub, Joseph D. Growney, Anne N. Murphy, Raymond Pagliarini, Christian M. Metallo, Shawn M. Davidson, Matthew G. Vander Heiden   +19 more
openalex   +1 more source

Supplementary Protocol from A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies

Curtis A. Lachowiez, Sanam Loghavi, Zhihong Zeng, Tomoyuki Tanaka, Yi June Kim, Hidetaka Uryu, Sven Turkalj, Niels Asger Jakobsen, Marlise R. Luskin, Dzifa Y. Duose, Rebecca S. Tidwell, Nicholas J. Short, Gautam Borthakur, Tapan M. Kadia, Lucia Masárová, George D. Tippett, Prithviraj Bose, Elias Jabbour, Farhad Ravandi, Naval Daver, Guillermo Garcia‐Manero, Hagop M. Kantarjian, Jacqueline S. Garcia, Paresh Vyas, Koichi Takahashi, Marina Konopleva, Courtney D. DiNardo   +26 more
openalex   +1 more source

Clinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutations. [PDF]

Oncologist
Nguyen MK, Jelinek M, Singh A, Isett B, Myers ES, Mullett SJ, Eisele Y, Beumer JH, Parise RA, Urban J, Rose A, Sellitto L, Singh K, Doerfler R, Dadey RE, Kim C, Rhee JC, Davar D, Villaruz LC, Burgess M, Drappatz J, Mantica M, Goodman AE, Wang H, Singhi AD, Luke JJ, Zandberg DP, Bao R.   +27 more
europepmc   +1 more source

FDA Approval Summary: Vorasidenib for IDH-Mutant Grade 2 Astrocytoma or Oligodendroglioma Following Surgery. [PDF]

Clin Cancer Res
Barbato MI, Barone AK, Aungst SL, Miller CP, Ananthula S, Bi Y, Yang Y, Li X, Xiong Y, Fan J, Dorff SE, Zhao H, Zhou H, Pradhan S, Scepura B, Sinha AK, Stephenson M, Bhatnagar V, Saber H, Rahman NA, Tang S, Pazdur R, Kluetz PG, Larkins E, Drezner N.   +24 more
europepmc   +1 more source

Unveiling prognosis in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax through novel risk stratification. [PDF]

Leuk Res Rep
Sun J, Guo Z.
europepmc   +1 more source